Encephalopathy represents a common and serious manifestation of HIV-1 infection in children, but its pathogenesis is unclear. We demonstrated that gp120 activated human brain microvascular endothelial cells (HBMEC) derived from children in up-regulating ICAM-1 and VCAM-1 expression, IL-6 secretion and increased monocyte transmigration across monolayers. Another novel observation was our demonstration of CD4 in isolated HBMEC and on microvessels of children's brain cryosections. Gp120-induced monocyte migration was inhibited by anti-gp120 and anti-CD4 antibodies. This is the rst demonstration that gp120 activates HBMEC via CD4, which may contribute to the development of HIV-1 encephalopathy in children. Journal of NeuroVirology (2001) 7, 125-134. 
Introduction
Encephalopathy represents a common and serious manifestation of HIV-1 infection in children. Approximately half of children with AIDS develop central nervous system (CNS) complications, which are directly attributable to HIV-1 infection. The virus has been shown to enter the CNS early in the course of HIV-1 infection (Epstein et al, 1986; Wiley et al, 1986; Berger et al, 1987; Grant et al, 1987) . At present, it is unclear how HIV-1 enters the brain and causes encephalopathy. HIV-1 may directly infect brain endothelium (Moses et al, 1993; Poland et al, 1995; Edinger et al, 1997) , enter endothelium via absorptive endocytosis (Banks et al, 1997) or enter the CNS using the Trojan Horse mechanism via transmigration of HIV-1 infected monocytes (Persidsky et al, 1997) . Once HIV-1 is inside the CNS, a cascade of events is triggered, which include infection of microglia, secretion of arachidonic acid metabolites, IL-1, TNF-®, TGF-¯1, macrophage colony stimulating factor, nitric oxide, platelet-activating factor, IL-6, chemoattractants for enhancing transmigration of HIV-1 infected monocytes/macrophages (Wahl et al, 1989; Lipton et al, 1994; Koka et al, 1995; Lafeuillade et al, 1996; Hittinger et al, 1998) and neuronal apoptosis (Bagetta et al, 1995) . All these events potentially contribute to the pathogenesis of HIV-1 encephalopathy.
In HIV-infected patients, HIV-1, viral cofactors or proteins (e.g., tat or gp120 shed into the circulation by HIV-1 and HIV-1-infected cells), or viral-induced cytokines (e.g. TNF®, IL-6) may act on the brain endothelium, which constitutes the blood-brain barrier (BBB) and allow the entry of HIV-1 and/or HIV-1-infected monocytes/macrophages into the CNS. Since little is known about the role of brain endothelium in the pathogenesis of HIV-1 encephalopathy, we developed an in vitro model of the BBB by culturing brain microvascular endothelial cells from children. We showed that children's HBMEC express CD4 and gp120 activates HBMEC in a CD4-dependent manner.
Results
CD4 is present on isolated pediatric HBMEC HB MEC were positive for Factor VIII-Rag, gamma glutamyl transpeptidase, and took up acetylated LDL . No GFAP positive cells were found and very few cells stained positive for alpha smooth muscle cells, indicating that HBMEC cultures were more than 95% pure. FACS sorting of HBMEC resulted in >99% purity .
The presence of CD4 on pediatric HBMEC was shown by three different techniques. First, FACS analysis of HBMEC incubated with anti-CD4 monoclonal antibody revealed that 58% cells were positive for CD4 (Figure 2A ). Second, RT-PCR of FACS sorted (>99% pure) pediatric HBMEC as well as CD4-positive lymphocytes revealed the PCR product (0.76 kb) corresponding to the expected size for the speci c primers of CD4 ( Figure 2B ) and DNA sequencing of the PCR product veri ed CD4 (Parnes, 1989) . A negative control of HBMEC without RT step con rmed that the product was not due to the presence of genomic DNA. In contrast, using the same primers, CD4 could not be detected from HUVEC ( Figure 2B ) and adult HBMEC (not shown). Third, immunocytochemistry of HBMEC with four different anti CD4 monoclonal antibodies revealed the presence of CD4 as indicated by the red precipitates ( Figure 2C ). Immunocytochemistry of HBMEC derived from three other children also showed positive staining for CD4, indicating that the presence of CD4 on brain endothelium is not unique to a particular child. Under similar conditions HUVEC did not show any staining for CD4 ( Figure 2D ). These ndings indicate that pediatric HBMEC possess CD4, whereas CD4 is absent from HUVEC and adult HBMEC.
CD4 is present on microvessels in frozen sections of children's brains Frozen sections of children's brain specimens incubated with anti-CD4 antibodies revealed a clear-cut staining associated with microvessel structures, indicating the presence of CD4 ( Figure 2E ). In contrast, CD4 staining was negative in sections derived from adult brain (not shown). These ndings show that CD4 is present on brain microvessels from children and support our demonstration that CD4 is present on pediatric brain endothelial cells.
Gp120 activated children's HBMEC: cell adhesion molecule expression and IL-6 secretion Gp120, shed from HIV-1 and HIV-1 infected cells, is shown to be present in the blood of HIV-1-infected patients (Schneider et al, 1986; Oh et al, 1992) and thus brain endothelium is likely to be exposed to circulating gp120. Since the major receptor for gp120 is the cell surface molecule CD4, we investigated whether pediatric HBMEC, which possesses CD4, would be responsive to gp120. Immunocytochemistry showed that gp120 concentrations ranging from 0.01 to 5 ¹g/ml were able to induce VCAM-1 and increase ICAM-1 expression after 4-24 h of incubation (not shown). Quantitation of VCAM-1/ICAM-1 expression by ELISA showed upregulation after 6-h incubation with gp120 derived from different T-tropic viruses, e.g., HIV-1 sf2, 2003 LAV, 2003 . No effect of gp120 on VCAM-1/ICAM-1 expression was found on HUVEC, whereas both LPS and TNF® (positive controls), as expected, induced robust expression of cell adhesion molecules on HUVEC ( Figure 3B ). Polymyxin B did not affect gp120-induced cell adhesion molecule expression on pediatric HBMEC (not shown), indicating that the gp120 effect was not due to a contamination of LPS. Gp120 (5 ¹g/ml) was able to induce IL-6 release from pediatric HBMEC, that is, 565 pg/ml of IL-6 was found in the medium after 6 h of incubation while TNF® as a positive control released 725 pg/ml. IL-6 release was not detectable in pediatric HBMEC incubated with medium alone. 
Gp120-induced transmigration of monocytes across children's HBMEC monolayers involves CD4
Because gp120 increased adhesion molecule expression on HBMEC, we next investigated the effect of gp120 on transendothelial migration of monocytes. Freshly isolated monocytes or vitamin D 3 differentiated HL60 cells were added to the upper compartment of Transwell TM tissue culture inserts containing pediatric HBMEC monolayers. Both gp120 (0.5 ¹g/ml) and LPS (100 ng/ml) enhanced monocyte transmigration over an 8-h period (3.1-fold and 1.9-fold increases, respectively) ( Figure 4A ). Figure 4B shows that gp120-induced monocyte migration was inhibited by monoclonal antibodies against CD4 and gp120, while irrelevant antibody (anti-HLA-I) did not have such an inhibitory effect. Polymyxin B had no effect on gp120-induced transmigration in HBMEC, indicating that gp120-induced transmigration was not due to LPS contamination. In contrast, gp120 did not induce any signi cant increase in monocyte migration in HUVEC, while LPS induced a 3.4-fold increase in monocyte transmigration ( Figure 4C ). Similar results were obtained with freshly isolated monocytes. These results indicate that increased transmigration of monocytes/HL60 cells across HBMEC in response to gp120 is speci c for pediatric brain endothelial cells, which occurs via a CD4-dependent manner. Because endothelial barrier models were used (>99% pure HBMEC), it is unlikely that our results are due to contaminating nonendothelial cells.
Involvement of chemokine receptors in gp120-induced transmigration of monocytes across children's HBMEC monolayers As gp120 is a ligand (B) TNF® (10 ng/ml) and LPS (50 ng/ml) but not gp120 (0.5 ¹g/ml) increase VCAM-1 and ICAM-1 expression on HUVEC. Bars indicate standard deviation. TNF®-and LPS-induced increases in VCAM/ICAM expression were statistically different from the control, whereas gp120 did not differ from the control (F D 1062, T range D 0.01-45, P < 0:001).
Figure 4
Monocyte transmigration across pediatric HBMEC monolayers. (A) A time-dependent increase in transmigration of HL60 cells was induced by both gp120 (0.5 ¹g/ml) and LPS (100 ng/ml). Bars indicate standard deviation. (B) Gp120 (0.5 ¹g/ml) induced transmigration at 2 h was inhibited by anti-CD4 and anti-gp120 antibodies (T range D 4.6-6.2, P < 0:001), but not by anti-HLA-1 antibody (control). Addition of polymyxin B did not inhibit gp120-induced monocyte transmigration. Bars indicate standard deviation. (C) Gp120 (0.5 ¹g/ml) for 4 h did not increase monocyte transmigration across HUVEC, whereas LPS (100 ng/ml) (positive control) increased monocyte migration. The addition of anti-gp120 or anti-CD4 antibody did not affect monocyte transmigration in the presence of gp120 in HUVEC (mean of duplicate experiments).
for both CD4 and chemokine coreceptors, the possible involvement of chemokine coreceptors in gp120-mediated transmigration was investigated ( Figure 5 ). RANTES (100 ng/ml) increased monocyte transmigration by 21%, however this increase was not statistically different from the control. Gp120 increased monocyte migration by 100% and antibodies against CXCR4, CCR3, CCR5, or isotype-matched control antibody did not signi cantly affect gp120-induced transmigration. This indicates that chemokine coreceptors do not play a major role in gp120-induced transmigration of monocytes across pediatric HBMEC.
Discussion
In children, HIV-1 infection is frequently accompanied by serious neurologic dysfunction. Epstein et al (1986) , have reported that progressive encephalopathy occurs in more than 50% of children with HIV-1 infection and the outcome is usually fatal. More recently, Cooper et al (1998) reported the presence of encephalopathy in 27% of HIV-1-infected children. Moreover, encephalopathy has been shown to represent the rst AIDS-de ning condition in 67% of the children and in 26% of children it was the only AIDS-de ning condition (Cooper et al, 1998) . HIV-1-associated neurologic dysfunction occurs in the absence of opportunistic infections, implying the limited role of co-infection in the pathogenesis of HIV-1 encephalopathy (Cooper et al, 1998) . The CNS, along with the immune system, are therefore important targets for HIV-1, especially in children.
It is unclear how HIV-1 enters the CNS and causes encephalopathy. There are several hypotheses about how HIV-1 crosses the brain endothelium and enters the CNS. For example, HIV-1 may infect the brain endothelium (Moses et al, 1993; Poland et al, 1995; Edinger et al, 1997) . Brain endothelial cells from monkey and cat have been shown to be infected with SIV or FIV, respectively (Lafon et al, 1993; Mankowski et al, 1994; Edinger et al, 1997; Strelow et al, 1998) . It remains, however, controversial whether brain endothelial cells derived from humans can be infected with HIV-1. Another possibility is that cell associated HIV-1 may cross the brain endothelium into the CNS as demonstrated by the presence of monocyte/macrophages around the brain microvessels in patients with HIV-1 CNS infection (Wiley et al, 1986) . In addition, an impairment of the barrier function of the endothelium may allow cell-free and cell-associated HIV-1 to enter the CNS. For example, signs of endothelial activation and damage have been reported in HIV-1-infected patients, e.g., increases in MHC expression, VCAM-1 expression, monocyte adherence, von Willebrand factor concentration and plasminogen activator inhibitor, decreases in protein S levels, and leakage of serum components into the CNS (Elovaara et al, 1991; Lafeuillade et al, 1992; Singer et al, 1994; Zietz et al, 1996; Stefano et al, 1998) . We have previously shown that TNF® activation of the brain endothelium increases HIV-1 crossing of the BBB by a paracellular mechanism . Increased VCAM-1 expression and monocytes adherence to endothelium have also been reported in SIV infection in macaques (Sasseville et al, 1992; Sasseville et al, 1994) . Circulating gp120 (Schneider et al, 1986; Gelderblom et al, 1987; Willey et al, 1994; ) is also likely to come into contact with the brain endothelium.
In this study, we showed for the rst time that gp120 is able to activate human brain endothelial cells, e.g., IL-6 secretion, VCAM-1, ICAM-1 expression, and monocyte migration. Gp120 concentrations in plasma and tissues of HIV-infected patients are unclear but the concentrations used in this report (0.01 to 5 ¹g/ml) are similar to those reported in the serum of AIDS patients (Oh et al, 1992) . More importantly, we showed for the rst time that CD4 is present on isolated HBMEC from children as shown by immunocytochemistry, RT-PCR, and FACS analysis. The presence of CD4 on pediatric brain endothelium in situ was demonstrated on frozen sections of brain tissues. The involvement of CD4 in gp120-induced monocyte migration was demonstrated by inhibition with anti-CD4 antibodies. Gp120-mediated activation of HBMEC was speci c to pediatric brain endothelial cells. Gp120 did not induce VCAM-1/ICAM-1 up-regulation and monocyte transmigration in HUVEC, and we failed to demonstrate CD4 on HUVEC. These ndings indicate that CD4 in pediatric brain endothelial cells is functionally interactive with gp120 and contributes to gp120-mediated activation of HBMEC.
CD4 is not restricted to the immune system and also shown to be present on glial cells, neurons, and colorectal epithelial cells (Maddon et al, 1986; Cheng-Mayer et al, 1987; Funke et al, 1987; Adachi et al, 1998) . It is, however, controversial whether CD4 is present on endothelial cells. CD4 has been reported to be present on microvascular endothelial cells of the human hepatic sinusoid (Nagura et al, 1986) . In contrast, CD4 was found to be absent on portal liver endothelium and macrovascular HUVEC (Lafon et al, 1992; Conaldi et al, 1995; Corbeil et al, 1995) . Other investigators also failed to demonstrate CD4 on brain endothelial cells derived from adults (Moses et al, 1993; Poland et al, 1995) . In agreement with those ndings, we were not able to show the presence of CD4 on adults' human brain endothelial cells. These ndings suggest that the role of brain endothelial cells in the pathogenesis of HIV-1 encephalopathy may differ between children and adults. An equally intriguing question is whether or not pediatric HBMEC, which possesses CD4, can be permissive for HIV-1 infection. Of interest, our preliminary investigations revealed that pediatric HBMEC expresses chemokine coreceptors, CCR3 and CCR5. However, as shown in this report, antibodies against both ®-and¯-chemokine coreceptors did not affect monocyte transmigration, suggesting that chemokine coreceptors are not likely to be a major contributor to gp120-mediated transmigration of monocytes across pediatric HBMEC. In contrast, Edinger et al (1997) have shown that CCR5 can serve as a CD4-independent receptor in simian immunode ciency virus (SIV) infection of Rhesus brain capillary endothelial cells. Additional studies are needed to elucidate the role of chemokine receptors in HIV-1 and SIV activation/infection of brain microvascular endothelial cells in humans and primates.
We also showed that gp120 increased monocyte transmigration across pediatric HBMEC monolayers. We have previously shown that immune activation of monocytes increases transmigration of monocytes across both adult and pediatric HBMEC monolayers (Persidsky et al, 1997) . Thus, it is possible that increased transendothelial migration of monocytes may be due to the activation of monocytes by gp120. However, gp120 did not induce signi cant increase in migration of monocytes across HUVEC, suggesting that gp120-mediated activation of monocytes is unlikely to be involved in gp120-mediated enhancement in transendothelial migration of monocytes. In addition, we have previously shown that HIV-1 infection of monocytes contributed to transendothelial migration of monocytes (Persidsky et al, 1997) . Independently, we observed that gp120 increased phosphorylation of PECAM-1 (unpublished results). We have previously shown that PECAM-1 phosphorylation is associated with transendothelial migration of monocytes across pediatric HBMEC Sultana et al, 1996) . Studies are in progress to elucidate the mechanisms of gp120-induced transendothelial migration of monocytes across childrens' HBMEC.
Gp120 has been shown to elicit neurotoxic substances (e.g., cytokines, arachidonic acid metabolites) (Wahl et al, 1989; Lipton et al, 1994; Koka et al, 1995; Yeung et al, 1995) in brain cultures, increase intracellular calcium (Dreyer et al, 1990) and induce apoptosis in neurons (Bagetta et al, 1995; Lannuzel et al, 1997; Hesselgesser et al, 1998) . In the present study, we demonstrated that gp120-induced up-regulation of VCAM-1 and ICAM-1 expression and transendothelial migration of monocytes in pediatric HBMEC. Taken together, these ndings indicate that gp120 may contribute to the development and progression of HIV-1 CNS infection by allowing increased migration of monocytes across the BBB and also inducing neuronal injury.
In summary, we demonstrated for the rst time that gp120 activates pediatric brain microvascular endothelial cells (secretion of IL-6, up-regulation of VCAM-1 and ICAM-1 expression, and monocyte migration) via a CD4-dependent manner.
Materials and methods

Isolation and culture of human brain microvessel endothelial cells (HBMEC)
Human brain capillaries were isolated and cultured as described previously . Brie y, small fragments of cerebral cortex were obtained from surgical resections of 4-7-year-old children with seizure disorders at Childrens Hospital Los Angeles and kept on ice unless otherwise indicated. Adult brain specimen was obtained from adult (»35 years) with seizure disorder. Visible larger blood vessels, if present, were carefully removed. Brain specimens were cut into small pieces and homogenized in Dulbecco's Modi cation of Eagles Medium containing 2% fetal bovine serum (DMEM-S) using a Dounce homogenizer with a loose tting. The homogenate was centrifuged in 15% dextran in DMEM-S for 10 min at 10 000 g. The pellet containing crude microvessels was further digested in a solution containing 1 mg/ml collagenase/dispase in DMEM-S for 1 h at 37 ± C. Microvascular capillaries were isolated by absorption to a column of glass beads and washing off the beads.
Human brain microvessels were plated on rat tail collagen and bronectin coated dishes or glass coverslips and cultured in RPMI 1640-based medium with 10% fetal bovine serum (FBS), 10% NuSerum, endothelial cell growth supplement (30 ¹g/ml) (Collaborative Biomedical Products, B&D, Bedford, MA), heparin (5U/ml), L-glutamine (2 mM), sodium pyruvate (1 mM), MEM nonessential amino acids, MEM vitamins, penicillin, and streptomycin (100 U/ml) (Irvine Scienti c, lrvine, CA). Cultures were incubated at 37 ± C in a humid atmosphere of 5% CO 2 and characterized as described previously . The endothelial cultures were more than 95% pure. FACS sorting of pediatric HBMEC was done as previously described , yielding more than 99% pure endothelial cell populations.
FACS analysis and Immunocytochemistry of pediatric HBMEC for CD4
Con uent pediatric HBMEC were lifted with EDTA, incubated with mouse monoclonal antibody to CD4 (1:20) (Gentrack, Plymouth Meeting, PA) or nonimmune ascites as a control for 30 min at 4 ± C, washed, incubated with FITC coupled goat anti-mouse lgG (Dako, Carpinteria, CA), xed with paraformaldehyde and analyzed by ow cytometry on a FACSscan. Lymphocytes known to be positive for CD4 were used as a positive control. Results were reported as percentage positive cells.
Immunocytochemistry for CD4 was done on HBMEC-cytospin slides and frozen sections of pediatric brain tissue using the avidin-biotin complexed to peroxidase (ABC-PO) method (Vector Labs, Burlingame, CA) as described previously . Anti-CD4 (Dako) was used in 1:20 dilution and CD4 hybridoma antibody SIM2, SIM4
(1:5 to 1:30) was from Dr James Hildreth obtained through the Reference Reagent Program, DAIDS, NIAID, NIH. Peroxidase color was developed with 3-amino-9-ethylcarbazole according to the manufacturer's instructions (Vector, Burlingame, CA) and cells/sections were counterstained with hematoxylin. Control ascites of nonsecretory myeloma, control isotype-matched antibody (Sigma, St Louis, MO) and omission of the primary and/or secondary antibody resulted in the absence of staining.
RT-PCR ampli cation of pediatric HBMEC
Total RNA was isolated from FACS sorted (>99% pure, clone AS4-3a) pediatric HBMEC , using the guanidine isothiocyanate method. In addition, RNA was isolated from CD4 lymphocytes and from HUVEC (Clonetics, San Diego, CA). RT-PCR was done as described previously (Huang, 1997) . Brie y, 1 ¹g of RNA was added to a mixture of 1X AMV reverse transcription buffer (Promega, Madison, WI), 2.5 mM MgSO 4 , 0.5 mM deoxynucleotide triphosphate (Perkin Elmer, Branchburg, NJ), 50 pmol of each primer, AMV transcriptase, and T f l DNA polymerase (Promega) in a nal volume of 50 ¹l. Reverse transcription was performed at 48 ± C for 45 min. Ampli cation was carried out in a Thermocycler (MJ Research, Waltham, MA) for 40 cycles: denaturation for 1 min at 94 ± C; primer annealing for 1 min at 60 ± C; primer extension for 3 min at 70 ± C. The following primers were used for a 0.76-kb CD4 fragment (189-953): 5 0 primer, 5 0 ACTGACCTGTACAGCTTC-3 0 , and 3 0 primer, 5 0 -CCAGCATACTGAGGCAAG-3 0 . These primers were synthesized on an Applied Biosystems 380B DNA synthesizer (Foster City, CA). The PCR product was resolved on 0.8% agarose gel. The PCR DNA was con rmed by DNA sequencing with sequenase (US Biochemical Corporation, Cleveland, OH).
Activation of pediatric HBMEC by gp120
Con uent pediatric HBMEC were treated with gp120 (0.01-5 ¹g/ml) in RPMI with 10% FBS for the indicated time. Thereafter, incubation medium was removed and IL-6 secretion was determined by ELISA as previously described (Arditi et al, 1995) . Gp120 preparations were obtained through the Reference Reagent Program, DAIDS, NIAID, NIH: gp120 from HIV-SF2 (#386) from Dr Kathleen Steimer, Chiron Corp (Levy et al, 1984; Sanchez-Pescador et al, 1985; Haigwood et al, 1990; Scandella et al, 1993) Expression of VCAM-1 and ICAM-1 was assessed immunocytochemically on cytospins slides and quanti ed by ELISA using antibodies against VCAM-1 and ICAM-1 (1:1000) (Immunotech, Westbrook, ME) using the ABC-PO or ABC-alkaline phosphatase (ABC-AP) method as described previously . Brie y, con uent HBMEC was treated with gp120 (0.5 ¹g/ml) or TNF® (10 ng/ml) for the indicated time, xed with acetone/methanol (1:1, V:V), incubated with the appropriate antibodies and color developed. For ELISA, ABC-AP was developed using p-nitrophenyl phosphate substrate and the absorbency at 405 nm was read (Molecular Devices, Menlo Park, CA). The results were expressed as relative optical density as mean of duplicate or triplicate ( §SD) after subtracting the blank value (determined in the absence of the primary antibody).
Gp120 induced transmigration of monocytes across pediatric HBMEC monolayers
To assess the effect of gp120 on monocyte migration across a single cell-type blood-brain barrier model, HBMEC (>99% pure) were seeded on collagen/ bronectin coated Transwell TM polycarbonate tissue culture inserts (12-well, Corning Costar, Cambridge MA) and grown to con uence. This allows separate access to the upper chamber (500 ¹l) and lower chamber (1500 ¹l). Con uent HBMEC were treated with gp120 (0.5 ¹g/ml) or LPS (E: coli O111:B4) (50-100 ng/ml) (List Biochemicals, Campbell, CA) for the indicated time periods. Freshly isolated monocytes (Kalra et al, 1994) or monocyte-like vitamin D 3 -differentiated HL60 cells (Languino et al, 1995; Hickstein et al, 1987) 1 £ 10 5 cells/well (ATCC, Bethesda, MD) were added to the upper chamber and allowed to migrate to the bottom chamber. At the indicated times, 100-¹l samples from the lower compartment were taken and the number of transmigrated monocytes counted as previously described . Similar results were obtained with freshly isolated monoctes and with monocytelike vitamin D3-treated HL60 cells. Monocyte migration was also assessed in the presence of monoclonal antibodies against CD4 (10-40 ¹g/ml), gp120 (10-40 ¹g/ml), or HLA-1 (Dako, Carpinteria, CA), anti-chemokine receptor antibodies (5-10 ¹g/ml) or lgG2a (Sigma, St Louis MO). Antibodies against CD4, gp120 and chemokine receptors were from NIH-AIDS Reference Reagent Program, DAIDS, NI-AID, and the concentrations used were shown to block ligand and gp120 binding. Monoclonal antibody to CD4 (Q4120) was from Dr Quentin Sattenau (Healey et al, 1990) and monoclonal antibody to HIV-1gp120 (0.5¯) was from Dr Shuzo Matsushita (Matsushita et al, 1988) . Anti-chemokine receptor monoclonal antibodies included CXCR4 (12G5) from Dr James Hoxie (Endres et al, 1996) , CCR5 (2D7) from Pharmigen, and CCR3 (7B11) from Leukocyte Inc (Heath et al, 1997) .
Statistical analysis
For statistical analysis ANOVA with planned pairwise comparison utilizing T distribution was used.
